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Abstract
Background:  The tissue accumulation of protein-bound advanced glycation endproducts (AGE)
may be involved in the etiology of diabetic chronic complications, including osteopenia. The aim of
this study was to investigate the effect of an AGE-modified type I collagen substratum on the
adhesion, spreading, proliferation and differentiation of rat osteosarcoma UMR106 and mouse non-
transformed MC3T3E1 osteoblastic cells. We also studied the role of reactive oxygen species
(ROS) and nitric oxide synthase (NOS) expression on these AGE-collagen mediated effects.
Results:  AGE-collagen decreased the adhesion of UMR106 cells, but had no effect on the
attachment of MC3T3E1 cells. In the UMR106 cell line, AGE-collagen also inhibited cellular
proliferation, spreading and alkaline phosphatase (ALP) activity. In preosteoblastic MC3T3E1 cells
(24-hour culture), proliferation and spreading were significantly increased by AGE-collagen. After
one week of culture (differentiated MC3T3E1 osteoblasts) AGE-collagen inhibited ALP activity, but
had no effect on cell number. In mineralizing MC3T3E1 cells (3-week culture) AGE-collagen
induced a decrease in the number of surviving cells and of extracellular nodules of mineralization,
without modifying their ALP activity. Intracellular ROS production, measured after a 48-hour
culture, was decreased by AGE-collagen in MC3T3E1 cells, but was increased by AGE-collagen in
UMR106 cells. After a 24-hour culture, AGE-collagen increased the expression of endothelial and
inducible NOS, in both osteoblastic cell lines.
Conclusions:  These results suggest that the accumulation of AGE on bone extracellular matrix
could regulate the proliferation and differentiation of osteoblastic cells. These effects appear to
depend on the stage of osteoblastic development, and possibly involve the modulation of NOS
expression and intracellular ROS pathways.
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Recent research indicates that an increase in the steady-
state levels of highly reactive dicarbonylic compounds
("carbonyl stress") may lead to the formation of ad-
vanced glycation endproducts or AGE. These AGE prod-
ucts could be involved in the etiology of the long-term
complications of several human afflictions, such as Dia-
betes mellitus, ageing, uremia and Alzheimer's disease
[1,2]. In diabetic patients with long-standing hyperglyc-
emia, an increase in the generation of AGE products can
be partly explained by the process of non-enzymatic gly-
cosylation of proteins. In this reaction, glucose reacts re-
versibly with the free amino groups of proteins to form
unstable Schiff bases, which may undergo an intramo-
lecular rearrangement giving rise to the more stable
Amadori product. A further modification of this product
originates 3-deoxyglucasone, a reactive dicarbonylic
non-protein-bound molecule, which can then form ad-
ducts with nearby proteins and irreversibly progress to
the formation of a family of compounds collectively
known as AGE, many of which are fluorescent and origi-
nate protein-proteins crosslinks [2]. Most studies have
demonstrated that AGE can induce structural and func-
tional alterations of various proteins.
Cell surface receptors for AGE moieties have been de-
tected on different cell types. These proteins appear to
contribute to diverse cellular functions, such as the spe-
cific recognition and degradation of AGE-modified pro-
teins [3]. Depending on the cell type involved, cellular
recognition of AGE can be associated with chemotaxis,
angiogenesis, oxidative stress, and either cell prolifera-
tion or apoptosis. Recent studies have suggested that the
nitric oxide synthase (NOS) / nitric oxide (NO) pathway
may be involved in the AGE-mediated alterations ob-
served in several cell types, such as retinal vascular en-
dothelial cells and macrophages [4,5]. In addition, NO-
mediated vasodilation has been reported to be impaired
in diabetes [6].
Collagenous proteins play important roles in the func-
tion of several tissues, including bone. They have a long
half-life and various free amino groups which are ex-
posed to ambient glucose levels [7]. An increase in AGE-
modified collagen has been detected in the cortical bone
of diabetic and ageing rats [8–10]. The alterations
caused by AGE-modifications of collagen may play a role
in the pathogenesis of the osteopenia present in poorly
controlled diabetic patients [11]. This osteopenia has
been attributed to a long-term decrease in the recruit-
ment and bone-forming activity of osteoblasts [12].
In our laboratory we have previously demonstrated that
soluble AGE-modified proteins can regulate the growth
of mouse MC3T3E1 and rat UMR106 osteoblast-like
cells:while initially eliciting an increase in cellular prolif-
eration and differentation, a relatively long-term incuba-
tion of these cells with AGE-modified bovine serum
albumin (BSA) induces a significant decrease in both pa-
rameters [13]. We have also described the presence of
membrane-associated receptors in both cell lines, which
specifically participate in the recognition and degrada-
tion of AGE-modified proteins. The expression of these
receptors is differentially regulated according to the os-
teoblastic stage of development [14]. Furthermore, we
have observed in this system [15] that AGE-BSA can
modify the secretion of insulin-like growth factor (IGF)-
I, one of the major growth factors involved in bone devel-
opment [16]. In addition, the levels of IGF-binding pro-
teins present in the osteoblastic conditioned media are
also regulated by AGE-BSA and the stage of osteoblast
development [15].
The aim of the present study was to investigate the effect
of an AGE-modified type I collagen matrix obtained in
vitro, on the adhesion, spreading, proliferation, differen-
tiation and mineralization of rat osteosarcoma UMR106
and mouse non-transformed MC3T3E1 calvaria-derived
cells in culture, throughout their different stages of oste-
oblastic development. In addition, we also studied the
role of reactive oxygen species (ROS) and NOS expres-
sion in the possible alterations of osteoblastic growth in-
duced by the glycated collagen matrix.
Results
Effect of an AGE-modified collagen matrix on cell adhe-
sion
Non-enzymatic glycosylation of the type I collagen ma-
trix induced cell-line specific alterations in cellular adhe-
sion (Fig. 1). As can be seen, the adhesion of
osteosarcoma UMR106 cells was significantly inhibited
by the AGE-modified collagen matrix (40 % inhibition).
However, the formation of AGE-products on the colla-
genous matrix caused no effect on the adhesion of non-
transformed MC3T3E1 cells.
Effect of AGE-collagen on cell proliferation
The effect of an AGE-modified collagen matrix on
UMR106 proliferation was evaluated by measurement of
cellular growth and spreading after 24 hours of incuba-
tion. When the cells were plated on an unmodified type I
collagen gel, they proliferated as expected, and about 70
% of them showed spreading (Fig. 2). However, when
cells were grown on AGE-modified collagen their prolif-
eration was significantly decreased (60 % of control), as
was the relative number of cells which showed spreading
(40 % of attached cells). The non-transformed MC3T3E1
cells were cultured on either control or glycated collagen
for different periods of time, in order for them to attain
different stages of osteoblastic development. In the pro-
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pected on the untreated collagen matrix, and about 30 %
of them showed spreading (Fig. 3). However, when they
were cultured on AGE-modified collagen for 24 hours, a
significant increase was observed both in cell prolifera-
tion (124 % of control) and in cellular spreading (42 % of
attached cells). After one week of culture (differentiated
stage), there was no statistically significant effect of
AGE-collagen on cell growth (Fig. 4). Finally, after three
weeks of culture (mineralizing stage), AGE-modified col-
lagen induced a statistically significant decrease in the
number of surviving cells (65 % of control).
Effect of AGE-collagen on osteoblastic differentiation and 
mineralization
In our culture system, cellular differentiation was evalu-
ated using specific ALP activity as a marker of mature os-
teoblastic phenotype. UMR106 osteosarcoma cells
expressed high levels of ALP (168 ± 8 nmol pNP / min ×
mg protein) when grown on an unmodified collagen ma-
trix. However, when they were cultured on an AGE-mod-
ified collagenous substratum, a significant decrease of
about 15 % was observed in their specific ALP activity
(Fig. 5). The non-transformed MC3T3E1 osteoblasts
grown on unmodified collagen, which initially (at 24
hours) expressed undetectable levels of ALP activity, in-
creased this expression to 2.77 ± 0.33 nmol pNP / min ×
mg protein after one week of culture in a medium supple-
mented with ascorbic acid and β-glycerol phosphate, and
reached a plateau of 3.05 ± 0.23 nmol pNP/ min × mg
protein after a three-week culture. When these cells were
cultured for one week on an AGE-modified collagenous
matrix, a 30 % decrease in ALP activity was observed
(Fig. 5). However, after three weeks of culture (mineral-
izing stage), no significant differences in specific ALP ac-
tivity were observed between cells grown on either kind
of matrix. The AGE-modified matrix was also found to
inhibit mineralization, the end point of MC3T3E1 oste-
oblastic differentiation. Cells growing for three weeks on
control type I collagen developed large areas of mineral-
ization, with microscopically prominent mineral nodules
(43 ± 5 calcified nodules per well). On the other hand,
AGE-modified collagen significantly inhibited the for-
mation of mineral nodules, which showed a much more
patchy distribution over the MC3T3E1 culture surface
Figure 1
Effect of an AGE-modified type I collagen matrix on cell
adhesion. UMR106 and MC3T3E1 osteoblast-like cells were
incubated on an unmodified collagen matrix or an AGE-colla-
gen matrix for 1 hour at 37°C. Cells adhering to the matrices
were fixed, stained with Giemsa and counted microscopically
at a magnification of 400X. Results are given as the number
of cells counted per field, and are expressed as the mean ±
SEM. Differences between collagen vs. AGE-collagen are as
follows: * p < 0.001
Figure 2
Effect of an AGE-modified type I collagen matrix on UMR106
cell proliferation and spreading. UMR106 osteosarcoma cells
were cultured on an unmodified collagen matrix or an AGE-
collagen matrix for 24 hours at 37°C. Cell proliferation was
evaluated by microscopically counting cells stained with
Giemsa, at a magnification of 400X. Cellular spreading was
also estimated microscopically, as the number of cells pos-
sessing at least two comers. Results are given as the number
of cells counted per field, and are expressed as the mean ±
SEM. Differences between collagen vs. AGE-collagen are as
follows: * p < 0.001
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trol collagen).
Role of ROS formation on AGE-induced osteoblastic devel-
opment
In order to investigate the role of ROS as possible medi-
ators of the AGE-collagen-induced osteoblast altera-
tions, proliferating osteoblast-like cells were loaded with
DHR and the intracellular content of the fluorescent ox-
idation product rhodamine was assessed. Fig. 6 shows
that AGE-modified collagen caused an increase in ROS
formation after 48 hours of UMR106 cell culture. On the
contrary, a statistically significant decrease in ROS for-
mation was detected in MC3T3E1 cells growing on AGE-
modified collagen versus control collagen.
Effect of AGE-collagen on the expression of NOS in oste-
oblast-like cells
We next examined the effect of an AGE-modified matrix
on the expression of endothelial constitutive (eNOS) and
inducible (iNOS) nitric oxide synthases, as evaluated by
Western blot analysis. The analysis of eNOS revealed a
band corresponding to a relative molecular mass of 135
kDa (Fig. 7). The expression of eNOS was found to be sig-
nificantly increased both in UMR106 and MC3T3E1 cells
after 24 hours of culture on AGE-collagen versus control
collagen. In addition, by using a specific anti-iNOS anti-
body, a protein of 130 kDa was detected (Fig. 8). The
AGE-modified collagen matrix versus control collagen
also significantly increased the intensity of this band in
both cell lines, after 24 hours of culture.
Discussion
It has been established that sustained hyperglycemia can
cause tissue damage through several mechanisms, in-
cluding the accelerated formation of AGE on proteins,
phospholipids and DNA [17]. An important consequence
of this non-enzymatic modification involves the recogni-
tion of the AGE moieties by specific plasma membrane
receptors, which can in turn induce alterations in cellular
functions by ROS-mediated mechanisms. The accumula-
tion of AGE occurs on both intracellular and extracellu-
lar structures (such as plasma and extracellular matrix
proteins [ECM]), altering their bioactivity and associa-
Figure 3
Effect of an AGE-modified type I collagen matrix on
MC3T3E1 cell proliferation and spreading. MC3T3E1 osteob-
lastic cells were cultured on an unmodified collagen matrix
or an AGE-collagen matrix for 24 hours at 37°C. Cell prolif-
eration was evaluated by microscopically counting cells
stained with Giemsa, at a magnification of 400X. Cellular
spreading was also estimated microscopically, as the number
of cells possessing at least two corners. Results are given as
the number of cells counted per field, and are expressed as
the mean ± SEM. Differences between collagen vs. AGE-col-
lagen are as follows: * p<0.01;  ** p<0.001.
Figure 4
Effect of an AGE-modified type I collagen matrix on
MC3T3E1 cell growth. MC3T3E1 calvaria-derived osteoblas-
tic cells were cultured on control collagen or AGE-modified
collagen at 37°C for one week (differentiated osteoblasts) or
three weeks (mineralizing cultures). The quantity of cells
growing on the corresponding collagenous matrices at each
timepoint, was evaluated by trypsinization and cell counting
with a haemocytometer. Results are given as the number of
cells counted in each case, and are expressed as the mean ±
SEM. Differences between collagen vs. AGE-collagen are as
follows: ** p<0.001.
BMC Cell Biology (2001) 2:16 http://www.biomedcentral.com/1471-2121/2/16tive properties. In particular, the accumulation of AGE
on bone type I collagen, which constitutes over 85% of
bone ECM proteins, has been previously described in
both diabetes and ageing [8–10]. The integrity of the
ECM is essential to maintain the normal function of os-
teoblasts, the main cell type involved in the formation of
bone [18]. Thus, AGE-modified ECM may have impor-
tant consequences on the normal bone-forming activity
of osteoblasts, possibly through changes in cell-matrix
interactions. Our present study confirms a previous re-
port [10] showing that the formation of AGE on type I
collagen can alter osteoblastic growth and inhibit osteob-
last differentiation. In addition, we have further extend-
ed that study by investigating the effect of AGE-modified
collagen on cell adhesion, its relationship to the stage of
osteoblastic development, and the possible involvement
of oxidative stress and NOS expression as mediators of
the action of AGE on osteoblastic cells.
Our results show that UMR106 osteosarcoma cells tend
to adhere less to AGE-collagen than to unmodified colla-
gen. However, no differences were found in the case of
the non-transformed MC3T3E1 line. These observations
seem to indicate that the effect of AGE modification of
ECM on cell attachment and growth could depend on cell
type. This concept is supported by reports from other in-
vestigators who have found either a decrease in cell ad-
hesion induced by AGE collagen in osteosarcoma MG63
cells, fibrosarcoma cells [19] and rat embryo 3Y1 fibrob-
lasts [20], or no effect of AGE on adhesion as in the case
of the osteosarcoma sub-clone UMR106-06 [21]. In this
context, the observed differences could be due to differ-
ent subsets of adhesion molecules involved in the attach-
ment to ECM by different cell types, for example in non-
transformed as opposed to tumorigenic cells. It has re-
cently been demonstrated that type I collagen interacts
with the α2β1 cellular integrin receptor [22,23]. The se-
quence Asp-Gly-Glu-Ala (DGEA) present in type I colla-
gen serves as the main recognition site for α2β1 integrin,
which has been dubbed the collagen-specific receptor. In
recent studies, Paul and Bailey [19] found that α2β1 is
probably involved in the attachment of MG63 osteosar-
coma cells to a collagenous matrix, since they were able
to inhibit cellular adhesion by an incubation with block-
ing anti-α2β1 antibodies. They also suggested, though did
not directly prove, that glycation of type I collagen with
methylglyoxal (a potent dicarbonylic AGE precursor)
modifies arginine residues present in its Arg-Gly-Asp
(RGD) sequence which is common to several other extra-
cellular matrix proteins, and normally is recognized by
the α5β1 integrin receptor [22]. Thus, the RGD sequence
is present in the procollagen molecule and could in theo-
ry mediate the interaction between bone cells and type I
collagen. In actual fact, since anti-α2 (but not anti-α5)
blocking antibodies inhibit cellular adhesion to a type I
collagen substratum, RGD-α5β1 interaction does not ap-
pear to be normally involved in the cellular attachment
to type I collagen [22,23]. However, it is conceivable that
different adhesion sequences of collagen could become
either exposed or masked for interaction with several
kinds of cellular receptors, as a consequence of molecu-
lar alterations of ECM such as AGE modification. Fur-
ther experiments are in progress in our laboratory to
investigate this hypothesis.
In this study we also examined the effect of AGE-modi-
fied collagen on osteoblastic proliferation and spreading,
differentiation (ALP activity) and mineralization (nodule
formation). The effect of AGE on cellular phenotypic ex-
pression was found to depend on cell type and/or the
stage of osteoblast development. AGE-modified collagen
Figure 5
Effect of an AGE-modified type I collagen matrix on the ALP
activity of UMR106 and MC3T3E1 cells. Osteoblastic cells
were cultured on control or AGE-modified type I collagen at
37°C either for 24 hours (UMR106 cells), or for one and
three weeks (MC3T3E1 cells). At the end of all incubations,
the cell monolayer was lysated in 0.1 % Triton X-100. Alka-
line phosphatase activity was determined in the lysates using
p-nitro-phenyl-phosphate as a substrate, and was normalized
for cellular protein content. Results are given as a percentage
of the corresponding basal condition (unmodified collagen),
and are expressed as the mean ± SEM. Differences between
collagen vs. AGE-collagen are as follows:  * p<0.01. Basal ALP
activity was 168 ± 8 nmol pNP / min x mg protein for
UMR106 cells; 2.77 ± 0.33 nmol pNP / min x mg protein for a
one-week culture of MC3T3E1 cells; and 3.05 ± 0.23 nmol
pNP / min x mg protein for a three-week culture of
MC3T3E1 cells.
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osteoblastic cells, but also diminished nodule formation
in post-mitotic osteoblasts in their mineralizing stage of
development. AGE-collagen also induced changes in cell
proliferation and spreading in a cell-type-specific man-
ner. Thus, after an incubation of 24 hours the glycated
matrix significantly inhibited growth and spreading in
osteosarcoma UMR106 cells. These observations are in
general agreement with the report of Paul and Bailey
[19], who found that AGE-collagen decreased the
number of matrix-attached MG63 osteosarcoma cells,
after an incubation of 20 hours. On the contrary, in the
case of non-transformed MC3T3E1 osteoblasts in their
proliferating stage of development (24-hour incubation),
AGE-modified collagen induced a significant increase in
cell growth and spreading. Similarly, in a recent report
[10] Katayama found an AGE-collagen-induced increase
of DNA synthesis in a primary culture of rat osteoblasts
after an incubation of 48 hours. The apparently discord-
ant results obtained in the two cell lines which we stud-
ied, may merely be the consequence of dissimilar
patterns of intracellular signaling between tumorigenic
and non-transformed cells, possibly as a reflection of dif-
ferent receptors involved in their recognition of control
or glycated matrices. In post-mitotic mineralizing
MC3T3E1 osteoblasts (3 weeks of culture), AGE-collagen
was associated with a significant decrease in the number
of surviving cells. However, since cells at this stage of de-
velopment do not divide, the observed effect may be ex-
plained by an AGE-induced acceleration of necrosis or
apoptosis in the mineralizing cultures. In fact, apoptosis
is the endpoint of most recruited osteoblasts in vivo, and
it has been shown that the products of different genes are
involved in the growth, differentiation and apoptosis of
osteoblast-like cells in culture [24].
We have previously described that in UMR106 and
MC3T3E1 cells, soluble AGE-BSA initially induces an in-
crease in cellular proliferation and differentiation, while
a relatively long-term incubation of these cells with AGE-
BSA elicits a significant decrease in both parameters
[13]. In addition, we have also shown that soluble AGE-
modified BSA alters the secretion of IGF-I and IGFBPs-
one of the main growth factor systems involved in oste-
oblastic progression and apoptosis- in a manner that is
dependent on the stage of osteoblastic development [15].
All of these AGE-BSA induced effects are most probably
a consequence of the recognition of soluble AGE struc-
tures by their receptors, which we have previously de-
scribed for both these cell lines [14]. On the other hand,
the relatively different osteoblastic response to AGE-col-
lagen which we report in the present study, may not only
be a consequence of the signal transduction mechanisms
induced by the occupancy of AGE-receptors, but also be
mediated by integrin or growth factor receptors, which
are intimately associated with the process of osteoblast
growth and differentiation. In summary, both previous
reports and our present study suggest a deleterious effect
of AGE-modified proteins on osteoblastic development.
To unravel the mechanisms by which AGE-modified col-
lagen may affect osteoblast development, we studied
ROS formation and NOS expression in our culture mod-
el. The formation of ROS was inversely correlated with
the AGE-collagen-induced changes in cellular prolifera-
tion. Thus, an increase in ROS formation was observed in
parallel with an inhibition of osteosarcoma UMR106 cell
growth. On the contrary, an AGE-mediated increase in
MC3T3E1 proliferation was associated with a decrease in
ROS formation. ROS have been found to be central to the
early stages of the transduction-signaling mechanism in-
itiated as a consequence of the recognition of AGE moie-
ties by their specific receptor RAGE [25,26]. This
signaling involves oxidation of p21ras by ROS, and subse-
quent activation of MAP kinases and NF-κB (a nuclear
transcription factor). In this sense, the AGE-induced
modulation of intracellular ROS levels may also be an
important regulator in the expression of certain subsets
of genes in osteoblastic cells.
We also assessed the effect of AGE-modified collagen on
the expression of NOS. There are a number of studies
that have linked an increase in the release of NO with hy-
perglycemia and diabetes [27–29]. In UMR106 as well as
in MC3T3E1 osteoblasts we have previously shown that
the release of NO is very low [30], and that eNOS and
iNOS are enhanced after culturing the cells with vanad-
ate, an agent that induces cytotoxicity in both cell lines.
The present study provides evidence which suggests that
eNOS and iNOS may be involved in the AGE-collagen-in-
duced events observed in osteoblastic cells. Culturing
UMR106 and MC3T3E1 osteoblasts for 24 hours on an
AGE-modified type I collagen matrix, significantly en-
hanced the expression of both NOS isoforms. Previous
studies have shown that pretreatment of macrophages
with AGE-BSA provokes an increase in the levels of LPS-
and IFN-γ-induced iNOS mRNA, an effect which is ac-
companied by an enhanced production of NO [6]. How-
ever, this effect is only observed in the presence of
cytokines: the incubation of macrophages with AGE-BSA
or unmodified BSA in the absence of cytokines does not
produce any increase in the nitrite levels. To our knowl-
edge, our present findings are the first to document an
effect of AGE-modified collagen on the expression of
non-cytokine stimulated iNOS in osteoblastic cells. We
also detected an even greater increment in the expres-
sion of the constitutive isoform eNOS after culturing os-
teoblast-like cells on an AGE-modified collagenous
matrix. These observations are in contrast with a previ-
ous report describing an inhibition of eNOS expression
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for 5 days with soluble glycated albumin [5]. The ob-
served differences may be due to the cell system under
study, to the time of AGE exposure, or more likely to the
cell surface receptors involved in the AGE-modified pro-
tein effects and the signaling pathways evoked after their
occupation. Nevertheless, the NO/NOS system very
probably represents a relevant regulatory mechanism
compromised in the cellular consequences of the accu-
mulation of AGE on extracellular matrix molecules.
Conclusions
The present study shows that the non-enzymatic glyco-
sylation of a type I collagen matrix induces alterations on
bone cells in culture, which are dependent on (a) cell type
and (b) the stage of osteoblastic development. In the os-
teosarcoma UMR106 cell line, AGE-collagen decreases
cellular attachment, spreading, proliferation, and ALP
activity. In pre-osteoblastic MC3T3E1 cells, AGE tran-
siently increases cell proliferation and spreading. When
these cells attain a mature osteoblastic phenotype, AGE-
modified collagen inhibits the expression of ALP, the for-
mation of calcified nodules of mineralization, and the
long-term survival of cells. Overall, these results seem to
indicate that AGE-collagen induces deleterious effects
on osteoblastic growth and function. If these mecha-
nisms were relevant in vivo, the accumulation of AGE on
bone extracellular matrix could contribute to the de-
crease in osteoblastic function which has been described
in diabetic patients with osteopenia. Furthermore, we
have presented evidence for the involvement of ROS and
NOS in the AGE-mediated effects on bone-producing
cells.
Figure 6
Effect of an AGE-modified type I collagen substratum on the
generation of intracellular reactive oxygen species by
MC3T3E1 and UMR106 cells. Osteoblasts were cultured at
37°C either on control collagen or on AGE-modified colla-
gen. After 48 hours, media were replaced by phenol red-free
DMEM with 10 µM dihydro-rhodamine, and cells were incu-
bated for an additional 4 hours. At the end of this incubation
the cell monolayers were lysated with 0.1 % Triton X-100,
and the levels of the oxidation product rhodamine were
measured in the lysates by the determination of fluorescence
intensity (excitation wavelength 495 nm, emission wave-
length 532 nm). Results are given as a percentage of the cor-
responding basal condition (unmodified collagen), and are
expressed as the mean ± SEM. Differences between collagen
vs. AGE-collagen are as follows:  * p<0.01;  ** p<0.001
Figure 7
Effect of AGE-modified type I collagen on the expression of
eNOS in osteoblast-like cells. UMR106 and MC3T3E1 cells
were cultured on control or AGE-modified type I collagen
matrices at 37ºC for 24 hours. After this incubation, cell
monolayers were lysated in Laemmli's buffer and electro-
phoresed under reducing conditions on an 8 % SDS-PAGE.
Western blotting was performed, and specific bands were
detected using a rabbit polyclonal antibody against eNOS. A
representative blot from three independent experiments is
presented (top figure). Images were scanned and analyzed by
densitometry. The relative intensity of each band is shown
(bottom figure) as a percentage of the corresponding basal
condition (unmodified collagen), and represents the mean ±
SEM. Differences between collagen vs. AGE-collagen are as
follows:  * p<0.02;  ** p<0.002 
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Materials
Rat tail acid-soluble type I collagen was purchased from
Sigma (St Louis, MO, USA). Dulbecco's modified Eagle's
medium (DMEM), trypsine-EDTA and fetal bovine se-
rum (FBS) were obtained from Gibco (Life Technology,
Argentina). Tissue culture disposable material was from
Nunc. Dihydrorhodamine 123 (DHR) was from Molecu-
lar Probes (Eugene, OR, USA). Polyclonal endothelial
and inducible nitric oxide synthase (eNOS and iNOS) an-
tibodies were from Research Biochemicals International
(RBI, MA, USA). All other chemicals and reagents were
obtained from commercial sources and were of analytical
grade.
Preparation of AGE-modified type I collagen for cell matri-
ces
Collagen was solubilized in sterile 0.02 N acetic acid (2.5
mg/ml) (pH 3.0), poured into plastic dishes (50 µg/cm2)
and incubated at 37°C. Collagen formed a thin film dur-
ing incubation [10]. The film was washed with phos-
phate-buffered saline (PBS) and further incubated with
or without 100 mM ribose in PBS at 37°C for 3 weeks in
sterile conditions [20]. Finally, the plates were exten-
sively washed with DMEM to eliminate excess ribose,
and the cells were plated for different experiments. Ri-
bose was used instead of glucose as the glycating sugar to
speed up nonenzymatic glycosylation. Kawano et al [20]
have shown that the sugar content in ribose-glycated col-
lagen increased 10-fold after 2 weeks of incubation, and
that the lysine and arginine content of collagen de-
creased 42 and 26 % respectively. In the present study,
AGE-formation on collagen was monitored by measur-
ing AGE-specific fluorescence emission (356 nm excita-
tion wavelength and 440 nm emission wavelength), as
we have previously described [13]. After incubating 3
weeks with ribose, collagen contained more AGE-associ-
ated fluorescence than control collagen incubated with
PBS alone (30 versus 7.5 relative fluorescence units / mg
protein, for AGE-modified and control collagen respec-
tively). In addition, the content of potentially reactive
free amino groups, estimated according to Lavy et al with
tri-nitro-benzene-sulphonic acid [31], decreased to 72 %
of control in the case of glycated collagen.
Cell culture
UMR106 rat osteosarcoma-derived cells were grown in
DMEM-10 % FBS and antibiotics. This cell line has been
shown to conserve certain characteristics of differentiat-
ed osteoblastic phenotype [32]. After 5–7 days, cells were
sub-cultured using trypsin / EDTA and replated on con-
trol and glycated collagen matrices to begin the experi-
ments. MC3T3E1 osteoblastic mouse calvaria-derived
cells were grown in 75 cm3 plastic flasks at 37°C in a hu-
midified 5 % CO2 atmosphere in DMEM supplemented
with 10 % FBS, 100 U/mL penicillin and 100 mg/L strep-
tomycin, and passaged every 4–6 days. Previous studies
have demonstrated that expression of osteoblastic mark-
ers begins after culturing these cells with medium sup-
plemented by β-glycerol-phosphate and ascorbic acid
[22,33]. When cells are cultured on collagen-coated
plates, ALP is expressed after 5 days. In addition, miner-
alization is achieved with these cells after extending this
culture to 20 days. However, the cells only undergo ac-
tive replication during the first 5 days of incubation. To
study the effect of AGE-collagen on cell growth in the dif-
ferent stages of MC3T3E1 osteoblastic development,
Figure 8
Effect of AGE-modified type I collagen on the expression of
iNOS in osteoblast-like cells. UMR106 and MC3T3E1 cells
were cultured on control or AGE-modified type I collagen
matrices at 37°C for 24 hours. After this incubation, cell
monolayers were lysated in Laemmli's buffer and electro-
phoresed under reducing conditions on an 8 % SDS-PAGE.
Western blotting was performed, and specific bands were
detected using a rabbit polyclonal antibody against iNOS. A
representative blot from three independent experiments is
presented (top figure). Images were scanned and analyzed by
densitometry. The relative intensity of each band is shown
(bottom figure) as a percentage of the corresponding basal
condition (unmodified collagen), and represents the mean ±
SEM. Differences between collagen vs. AGE-collagen are as
follows:  * p<0.05;  ** p<0.002
BMC Cell Biology (2001) 2:16 http://www.biomedcentral.com/1471-2121/2/16cells were grown under the conditions that we have pre-
viously reported [14] for the times indicated in each ex-
periment.
Cell adhesion assay
Osteoblast-like cells were plated on control or AGE-
modified collagen-coated 24 well plates at a seeding den-
sity of 2.5 × 105 cells/ml. Cells were allowed to adhere for
1 hour. Each well was then washed with PBS, fixed with
methanol for 5 minutes and stained with Giemsa for 10
minutes. Cells adhered to the collagen or AGE-collagen
matrices were evaluated microscopically by counting
several representative fields per well. A linear regression
of the adhesion assay occurred between 1 × 105 and 1 ×
106 cells/ml (y = 0.826 + 0.759 x, r= 0.993).
Cell proliferation assay
Cells were grown at 37°C on control or AGE-modified
collagen-coated 24 well plates (1 × 104 cells/ml).
UMR106 cell line was cultured for 24 hours, while
MC3T3E1 cells were incubated for 24 hours (proliferat-
ing cells), one week (differentiated cells) or 3 weeks
(mineralizing cells), changing the supplemented medi-
um every two days. Cell proliferation was assessed by
counting the cells as described above (for short periods
of culture) or by trypsinization and cell counting with a
haemocytometer (for 1 and 3 weeks of culture). Spread-
ing was assessed by counting the proportion of stained
cells which presented more than one corner, in several
representative microscopic fields per well.
Cell differentiation. Alkaline phosphatase activity (ALP) 
determination
Cells were plated in 24-well plates coated with control or
AGE-modified collagen, and were incubated at 37°C as
described above for 24 hours (both cell lines), one week
(MC3T3E1 cells) or three weeks (MC3T3E1 cells). At the
end of these incubation periods, each cell monolayer was
washed with PBS and solubilized in 0.1 % Triton X-100.
The ALP specific activity (a marker of osteoblastic phe-
notype) was assessed as has been previously described
[13,34].
Mineralization assay
To assess the mineralizing potential of MC3T3E1 cul-
tures, cells were grown for three weeks on control or
AGE-modified collagen matrices as described above. Cell
monolayers were stained using the von Kossa method as
we have previously described [15], and the number of
calcified nodules per dish was counted using a micro-
scope.
Determination of reactive oxygen species (ROS) formation
Intracellular ROS generation in osteoblast-like cells was
measured by oxidation of DHR to rhodamine as we have
previously described [35]. Osteoblasts were cultured on
either control or AGE-modified collagen at 37°C for 48
hours. Media were replaced by phenol red-free DMEM
with 10 µM DHR and the cells were further incubated for
4 hours. After washing with PBS, the monolayer was
lysated in 0.1 % Triton X-100. The oxidized product
present in the cell extract (rhodamine), was analysed by
measuring fluorescence (excitation wavelength 495 nm,
emission wavelength 532 nm).
Western blot analysis of nitric oxide synthases (NOS)
In order to evaluate the expression of NOS and the pos-
sible effect of AGE-collagen on these parameters, cells
growing on control or AGE-modified collagen matrices
were lysated in Laemmli buffer [36] and the protein con-
tent was evaluated by the method of Lowry [37]. The
lysate was heated at 100°C for 3 min and 15 µg of protein
subjected to 8% SDS-PAGE. The separated proteins were
then transferred to nitrocellulose membranes. After
washing and blocking, the membranes were incubated
with anti-iNOS or eNOS polyclonal antibodies as we
have previously described [30]. The intensity of the iNOS
or eNOS specific bands was quantified by densitometry
after scanning of the nitrocellulose paper. Images were
analysed using the Scion-beta 2 program.
Statistical analysis
Three independent experiments were run for each exper-
imental condition. Results are expressed as mean ± SEM.
Statistical analysis of the data was performed by Stu-
dent's t test.
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